Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Mallinckrodt
Argus Health
McKesson
Farmers Insurance
Covington
US Army
Citi
Accenture

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207958

« Back to Dashboard

NDA 207958 describes SPRITAM, which is a drug marketed by Aprecia Pharms Co and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the SPRITAM profile page.

The generic ingredient in SPRITAM is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-eight suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
Summary for 207958
Tradename:SPRITAM
Applicant:Aprecia Pharms Co
Ingredient:levetiracetam
Patents:4
Therapeutic Class:Anticonvulsants
Formulation / Manufacturing:see details
Pharmacology for NDA: 207958
Suppliers and Packaging for NDA: 207958
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958 NDA Aprecia Pharmaceuticals, LLC 43485-101 43485-101-60 60 BLISTER PACK in 1 CARTON (43485-101-60) > 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (43485-101-01)
SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958 NDA Aprecia Pharmaceuticals, LLC 43485-102 43485-102-60 60 BLISTER PACK in 1 CARTON (43485-102-60) > 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (43485-102-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, FOR SUSPENSION;ORALStrength250MG
Approval Date:Jul 31, 2015TE:RLD:Yes
Patent:➤ SubscribePatent Expiration:Feb 20, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ SubscribePatent Expiration:Mar 14, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF ADMINISTERING LEVETIRACETAM
Patent:➤ SubscribePatent Expiration:Feb 20, 2018Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Healthtrust
Accenture
Express Scripts
Teva
Cipla
Medtronic
Cantor Fitzgerald
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot